Abstract
Increased tumor markers in patients with liver cirrhosis are often considered to be unspecific. The use of this unspecific elevation to discriminate minimal fibrosis from severe fibrosis has never been explored. We aimed to answer the question, Do tumor markers predict severe liver fibrosis? The study group consisted of 125 patients with alcoholic liver disease, hepatitis B, or hepatitis C with available liver biopsy. Tumor markers CA 19-9, CA 15-3, and CA 125 were determined using routine laboratory methods and correlated with the extent of liver fibrosis. Fibrosis stages 1 and 2 were classified as minimal fibrosis; stages 3 and 4, as severe fibrosis.
Tumor markers CA 19-9, CA 125, and CA 15-3 increased with stage of fibrosis. For separating patients with mild fibrosis (F1+F2) from patients with severe fibrosis (F3+F4), CA 19-9 had a sensitivity of 70.5% and a specificity of 88.6, CA 125 had 38.1% and 89.7%, and CA 15-3 had 19.0% and 93.0%, respectively. Logistic regression of a combined score of CA19-9 and CA 125 values revealed that an increase of 1 point of the CA 19-9/CA125 score resulted in a 1.6 times increase in likelihood of the presence of severe fibrosis. The CA 19-9/CA 125 score achieved a similar specificity (97.1% vs. 100%) but a higher sensitivity (42.9% vs. 33.3%) than the widely used cirrhosis discriminant score of Bonacini. A specificity (98.5%) similar to that of the CA 19-9/CA 125 score was reached by the easier determination of the combined elevation of CA 19-9 and CA 125, which had the best positive predictive value, 92.9%. The excellent predictive ability of the combined elevation of CA 19-9 and CA 125 for severe liver fibrosis (F3+F4) was confirmed in an independent group of patients with liver disease. The combined elevation of CA 19-9 and CA 125 is useful for identifying patients with advanced fibrosis or cirrhosis with high specificity. Patients without a combined elevation of CA 19-9 and CA 125 still require histological examination to identify severe fibrosis or cirrhosis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Perrillo RP: The role of liver biopsy in hepatitis C. Hepatology 26(Suppl 1):57S–61S, 1997
Piccinino F, Sagnelli E, Pasquale G, Guisti G: Complications following percutaneous liver biopsy: a multicentre retrospective study on 68,276 biopsies. J Hepatol 2:165–173, 1986
3. Garcia-Tsao G, Boyer JL: Outpatient liver biopsy: how safe is it? Ann Intern Med 118:150–153, 1993
Piccinino F, Sagnelli E, Pasquale G, Giusti G: Complications following percutaneous liver biopsy: a multicenter retrospective study om 68,276 biopsies. J Hepatol 2:165–173,1986
Nord JH: Biopsy diagnosis of cirrhosis: blind percutaneous versus guided direct vision techniques. A review. Gastrointest Endosc 28:102–104, 1982
Teran JC, Bashour FN, Sondhi SS, Mullen KD: Validation of a discriminant score for the diagnosis of cirrhosis in patients with chronic hepatitis. Gastroenterology 108:A1185, 1995 (abstract)
Bonacini M. Hadi G, Govindarajan S, Lindsay KL: Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 92:1302–1304, 1997
Knoddel RG, Ishak KG, Black WC, et al.: Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:431–435, 1981
Saadeh S, Cammell G, Carey WD, Younossi Z, Barnes D, Easley K: The role of liver biopsy in chronic hepatitis C. Hepatology 33:196–200, 2001
Oberti F, Valsesia E, Pilette C, Rousselet MC, Bedossa P, Aubé C, Gallois Y, Rifflet H, Maïga MY, Penneau-Fontbonne D, Calès P: Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 113:1609–1616, 1997
Naveau S, Poynard T, Benattar C, Bedossa P, Chaput J-C: Alpha-2-macroglobulin and hepatic fibrosis. Dig Dis Sci 39(11):2426–2432, 1994
Molina R, Filella X, Bruix J, Mengual P, Bosch J, Calvet X, Jo J, Ballesta AM: Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases. Clin Chem 37(8):1379–1383, 1991
Zuckerman E, Lanir A, Sabo E, Rosenvald-Zuckerman T, Matter I, Yeshurun D, Eldar S: Cancer Antigen 125: A sensitive marker of ascites in patients with liver cirrhosis. Am J Gastroenterol 94:1613–1618, 1999
Collazos J: Clinical and laboratory evaluation of CA 19–9 in cirrhotic patients. Eur J Med 1(4):215–218, 1992
Canney PA, Moore M, Wilkinson PM, James RD: Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker. Br J Cancer 50(6):765–769, 1984
Touitou Y, Bogdan A: Tumor markers in non-malignant diseases. Eur J Cancer Clin Oncol 24(7):1083–1091, 1988 (review)
Ludwig J: Histopathological diagnosis and terminology of chronic hepatitis. J Hepatol 1:49–53, 1995
Deschenes M, Michel RP, Alpert E, Barkun JS, Metrakos P, Tchervenkov J: Elevation of CA-125 level is due to abdominal distension in liver transplantation candidates. Transplantation 72(9):1519–1522, 2001
Guyader D, Jacquelinet C, Moirand R, Turlin B, Mendler MH, Chaperon J, David V, Brissot P, Adams P, Deugnier Y: Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology 115(4):929–936, 1998
Collazos J, Genolla J, Ruibal A: CA 19-9 in non-neoplastic liver diseases. A clinical and laboratory study. Clin Chim Acta 210(1–2):145–151, 1992
Osswald BR, Klee FE, Wysocki S: The reliability of highly elevated CA 19-9 levels. Dis Markers 11(5–6):275–278, 1993
Kadayifci A, Simsek H, Savas MC, Toppare M: Serum tumor markers in chronic liver disease. Neoplasma 43(1):17–21, 1996
Collazos J, Genolla J, Ruibal A: Breast cancer-associated antigen CA 15.3 in liver cirrhosis. Acta Oncol 31(7):741–744, 1992
Collazos J, Genolla J, Ruibal A: CA 15.3 in nonmalignant liver diseases. Int J Biol Markers 6(3):188–192, 1991
Giannini E, Borro P, Botta F, Chiarbonello B, Fasoli A, Malfatti F, Romagnoli P, Testa E, Risso D, Lantieri PB, Antonucci A, Boccato M, Milone S, Testa R: Cholestasis is the main determinant of abnormal CA 19-9 levels in patients with liver cirrhosis. Int J Biol Markers 15(3):226–230, 2000
Mann DV, Edwards R, Ho S, Lau WY, Glazer G: Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 26(5):474–479, 2000
Romagnuolo J, Jhangri GS, Jewell LD, Bain VG: Predicting the liver histology in chronic hepatitis C: how good is the clinician? Am J Gastroenterol 96(11):3165–3174, 2001
Myers RP, Hilsden RJ, Lee SS: Historical features are poor predictors of liver fibrosis in Canadian patients with chronic hepatitis C. J Viral Hepat 8(4):249–255, 2001
Poynard T, Aubert A, Bedossa P, Abella A, Naveau S, Paraf F, Chaput JC: A simple biological index for detection of alcoholic liver disease in drinkers. Gastroenterology 100:1397–402, 1991
Teare JP, Sherman D, Greenfield SM, Simpson J, Bray G, Catterall AP, Murray-Lyon IM, Peters TJ, Williams R, Thompson RP: Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis. Lancet 342:895–898, 1993
Kanzler S, Baumann M, Schirmacher P, Dries V, Bayer E, Gerken G, Dienes HP, Lohse AW: Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta. J Viral Hepat 8(6):430–437, 2001
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schöniger-Hekele, M., Müller, C. The Combined Elevation of Tumor Markers CA 19-9 and CA 125 in Liver Disease Patients Is Highly Specific for Severe Liver Fibrosis. Dig Dis Sci 51, 338–345 (2006). https://doi.org/10.1007/s10620-006-3135-x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10620-006-3135-x